Navigation Links
Maximizing the Potential of Multi-Drug Portfolios without Undermining a Legacy Brand
Date:5/5/2011

CHAPEL HILL, N.C., May 5, 2011 /PRNewswire/ -- In today's highly competitive marketplace, bio-pharmaceutical companies often look to expand their product portfolios in the same indication. This "double-dipping" can result in a new brand gaining more profitability at the expense of a more established brand. The challenge for all product and brand leaders is to introduce the new product so that it does not affect the sales of the established brand while remaining competitive.

To help companies to meet this critical challenge, Best Practices, LLC has published "Expanding a Product Portfolio without Cannibalizing an Established Brand," a 61-page report that provides superior marketing and branding strategies for expanding a product portfolio without cannibalizing an existing brand.

While it can be a complex decision, having more than one brand in a therapeutic area clearly pays off for an organization - 96 percent of the study participants realized positive benefits of introducing a new brand treating an indication for which it had an existing product. More than 70 percent of the benchmark class identified market leadership, expanded market share and enhancing brand reputation among physicians as major contributing factors for marketing multiple products.

Participants in the study successfully used a range of positioning strategies to prevent or control cannibalization. Fifty percent or more of the benchmark class rated 10 positioning strategies somewhat effective to very effective at minimizing product cannibalization. Targeting different patient subtypes and aligning with thought leaders are among those positioning strategies rated effective by more than 80 percent of the benchmark class.

Topics covered in this study include:

  • Effective methods of differentiating multiple brands
  • Positioning strategies that minimize product cannibalization
  • Operational changes that drive success when introducing a new brand into a product family
  • Positive and negative impacts of introducing a new brand
  • New product's share of the combined marketing spend during first three years both are marketed
  • Marketing mix for new and legacy products
  • Marketing activities that drive continuing success for legacy brand
  • Best indicators of marketing effectiveness

Participants in this benchmarking research included 28 respondents at 22 leading pharmaceutical, biotech and medical device companies. Product and brand leaders can use this study to review successful strategies and tactics for managing resources and avoiding - or controlling - product cannibalization when marketing multiple brands for the same area of use.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1066.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. 


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Maximizing the Potential of Multi-Drug Portfolios Without Cannibalizing from a Legacy Brand
2. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
3. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
4. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
10. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
11. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a ... Miami, and Raleigh regions, is organizing an extended charity drive to benefit the ... chromosome abnormality. , After struggling since birth with several health challenges, T.J. was ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):